Article
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer's progression
Rating:
0.0
Views:
28
Likes:
1
Library:
1
Eisai and Biogen BIIB said Wednesday that their drug, lecanemab, reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in...
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value